Michael Austin Coker1, Zachary A Glaser1, Jennifer B Gordetsky1,2, John V Thomas3, Soroush Rais-Bahrami4,5. 1. Department of Urology, University of Alabama at Birmingham, Birmingham, AL, UK. 2. Department of Pathology, University of Alabama at Birmingham, Birmingham, AL, UK. 3. Department of Radiology, University of Alabama at Birmingham, Birmingham, AL, UK. 4. Department of Urology, University of Alabama at Birmingham, Birmingham, AL, UK. sraisbahrami@uabmc.edu. 5. Department of Radiology, University of Alabama at Birmingham, Birmingham, AL, UK. sraisbahrami@uabmc.edu.
Abstract
BACKGROUND: Magnetic resonance imaging (MRI)/ultrasound (US) fusion-guided biopsy has improved the ability to localize and detect prostate cancer (PCa) with efficiency surpassing systematic biopsy. Nevertheless, some patients have PCa missed using the MRI-targeted biopsy sampling alone. We aim to identify clinical and imaging parameters associated with cases where targeted biopsy did not detect PCa compared to systematic biopsy. METHODS: We conducted a retrospective review of patients who underwent MRI/US fusion-guided biopsy in addition to concurrent systematic, extended-sextant biopsy between 2014 and 2017. For patients with PCa detected on systematic biopsy not properly localized by MRI/US fusion-guided biopsy, the sextant distance from MRI-targeted lesion to the cancer-positive sextant was calculated and parameters potentially predicting this targeting miss were evaluated. RESULTS: In all, 35/127 (27.6%) patients with single-session MRI/US fusion-guided biopsy plus standard biopsy finding PCa had lesions incorrectly localized. Of these, 15/35 (42.9%) were identified as possible fusion-software misregistrations. The remainder, 12/35 (34.3%), represented targeted biopsies one sextant away from the cancer focus and 8/35 (22.9%) targeted biopsies two sextants away from the cancer focus. Only 7/35 (20.0%) patients were determined to have clinically significant PCa, which represents 7/127 (5.5%) of the overall population. Lower MRI lesion volumes (p = 0.022), lesion density (p < 0.001), and PI-RADS scores (p < 0.001) were significantly associated with targeted biopsy missing PCa detected on systematic biopsy. CONCLUSION: Clinically significant PCa is rarely missed utilizing MRI/US fusion-guided biopsy. With the majority of missed tumors representing targeting misregistrations or cases of low-grade cancer in sextants immediately adjacent to MRI suspicious lesions. Lower MRI lesion volumes, lesion density, and PI-RADS are predictors of cases with targeted biopsies missing cancer, for which systematic sampling of the sextants containing MRI targets and adjacent sextants would most optimize PCa detection.
BACKGROUND: Magnetic resonance imaging (MRI)/ultrasound (US) fusion-guided biopsy has improved the ability to localize and detect prostate cancer (PCa) with efficiency surpassing systematic biopsy. Nevertheless, some patients have PCa missed using the MRI-targeted biopsy sampling alone. We aim to identify clinical and imaging parameters associated with cases where targeted biopsy did not detect PCa compared to systematic biopsy. METHODS: We conducted a retrospective review of patients who underwent MRI/US fusion-guided biopsy in addition to concurrent systematic, extended-sextant biopsy between 2014 and 2017. For patients with PCa detected on systematic biopsy not properly localized by MRI/US fusion-guided biopsy, the sextant distance from MRI-targeted lesion to the cancer-positive sextant was calculated and parameters potentially predicting this targeting miss were evaluated. RESULTS: In all, 35/127 (27.6%) patients with single-session MRI/US fusion-guided biopsy plus standard biopsy finding PCa had lesions incorrectly localized. Of these, 15/35 (42.9%) were identified as possible fusion-software misregistrations. The remainder, 12/35 (34.3%), represented targeted biopsies one sextant away from the cancer focus and 8/35 (22.9%) targeted biopsies two sextants away from the cancer focus. Only 7/35 (20.0%) patients were determined to have clinically significant PCa, which represents 7/127 (5.5%) of the overall population. Lower MRI lesion volumes (p = 0.022), lesion density (p < 0.001), and PI-RADS scores (p < 0.001) were significantly associated with targeted biopsy missing PCa detected on systematic biopsy. CONCLUSION: Clinically significant PCa is rarely missed utilizing MRI/US fusion-guided biopsy. With the majority of missed tumors representing targeting misregistrations or cases of low-grade cancer in sextants immediately adjacent to MRI suspicious lesions. Lower MRI lesion volumes, lesion density, and PI-RADS are predictors of cases with targeted biopsies missing cancer, for which systematic sampling of the sextants containing MRI targets and adjacent sextants would most optimize PCa detection.
Authors: Frank-Jan H Drost; Daniël F Osses; Daan Nieboer; Ewout W Steyerberg; Chris H Bangma; Monique J Roobol; Ivo G Schoots Journal: Cochrane Database Syst Rev Date: 2019-04-25
Authors: Cheyenne Williams; Michael Ahdoot; Michael A Daneshvar; Christian Hague; Andrew R Wilbur; Patrick T Gomella; Joanna Shih; Nabila Khondakar; Nitin Yerram; Sherif Mehralivand; Sandeep Gurram; Minhaj Siddiqui; Paul Pinsky; Howard Parnes; Maria Merino; Bradford Wood; Baris Turkbey; Peter A Pinto Journal: J Urol Date: 2021-08-26 Impact factor: 7.450
Authors: Teodora Telecan; Iulia Andras; Nicolae Crisan; Lorin Giurgiu; Emanuel Darius Căta; Cosmin Caraiani; Andrei Lebovici; Bianca Boca; Zoltan Balint; Laura Diosan; Monica Lupsor-Platon Journal: J Pers Med Date: 2022-06-16
Authors: Christopher Antonio Febres-Aldana; Sarah Alghamdi; Thomas A Weppelmann; Emilio Lastarria; Akshay Bhandari; Yumna Omarzai; Robert J Poppiti Journal: Urol Ann Date: 2020-10-15
Authors: Jennifer B Gordetsky; David Ullman; Luciana Schultz; Kristin K Porter; Maria Del Carmen Rodriguez Pena; Carli E Calderone; Jeffrey W Nix; Michael Ullman; Sejong Bae; Soroush Rais-Bahrami Journal: Hum Pathol Date: 2018-09-01 Impact factor: 3.466
Authors: August Sigle; Cordula A Jilg; Timur H Kuru; Nadine Binder; Jakob Michaelis; Markus Grabbert; Wolfgang Schultze-Seemann; Arkadiusz Miernik; Christian Gratzke; Matthias Benndorf; Rodrigo Suarez-Ibarrola Journal: Cancers (Basel) Date: 2021-05-20 Impact factor: 6.639